A patient developed Stevens-Johnson Syndrome following armodafinil therapy for daytime sleepiness.
Associated cardiovascular side effects of bronchodilators may reduce prescription rates in patients with COPD with comorbid cardiovascular disease.
Patients with persistent hypercapnia following acute exacerbation of COPD, home noninvasive ventilation with home oxygen therapy prolonged readmission time.
Higher doses were independently linked to slower change in emphysema, especially among former smokers
Angiotensin II decreased the requirement to use catecholamines in patients with vasodilatory shock.
Two phase 3 clinical development programs showed improved breathing in children and adolescents with moderate-to-severe asthma regardless of allergic status.
Developed in Cuba, the TG4010 and CIMAvax-EGF vaccines are undergoing clinical study in the US.
Research presented at SLEEP 2017 suggests that dronabinol, previously used to treat chemotherapy-induced nausea and vomiting, may be an effective treatment for sleep apnea.
A retrospective cohort study examined squamous cell carcinoma outcomes in adult lung transplant recipients who received voriconazole.
NasalCom nasal spray has been recalled due to possible microbial contamination in the water used to manufacture the product.
Treatment with full-dose angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers was found to slow disease progression in patients with emphysema.
Mepolizumab resulted in longer remission periods with a larger proportion of participants in remission compared to the placebo, which resulted in reduced glucocorticoid use.
Patients with sepsis who received oral corticosteroids before intensive care unit admission were at reduced risk for acute respiratory distress syndrome.
Sublingual immunotherapy is associated with slower AR progression and less frequent asthma onset in patients with allergic rhinitis.
Allergen immunotherapy (AIT) was shown to reduce short-term symptoms and medication scores.
Researchers examined the relationship between COPD and right and left ventricular morphometry to determine which patients may better respond to beta-blocker therapies.
Over 2278 health subjects were included in a multicenter study of the Seqirus IIV4 quadrivalent inactivated influenza vaccine.
Hyperbaric oxygen therapy reduced the risk for short- and long-term mortality in patients younger than 20 who had carbon monoxide poisoning.
Imatinib demonstrated an improvement in mast-cell activity and airway hyperresponsiveness in severe refractory asthma vs placebo.
Researchers compared 4- and 8-week benralizumab vs placebo for asthma.
A new survey shows that home oxygen services create barriers for patients with lung disease.
Compared to the year prior to bronchial thermoplasty (BT) treatment, in the 2 years after BT treatment, patients experienced reduction in severe exacerbations, hospitalizations, and ER visits.
The FDA has expanded the approved indication of ivacaftor for cystic fibrosis, increasing the number of rare gene mutations the drug may be used to treat.
The TRINITY study reports the significant benefits to extafine triple therapy taken in a single inhaler compared with tiotropium in chronic obstructive pulmonary disease.
Simulated studies were key to the approval of roflumilast for reducing COPD exacerbations.
Mepolizumab showed early and sustained clinically relevant improvements in quality of life, with a good safety profile in severe eosinophilic asthma.
Patients with asthma have an increased risk of pneumonia when using inhaled corticosteroids, including budesonide and fluticasone.
Oral corticosteroids, regardless of dose or duration, may increase the risk of adverse effects in patients with severe asthma.
Sunovion announces Utibron Neohaler, an inhalation powder for the long term maintenance treatment of airflow obstruction in COPD patients.
The European Respiratory Society and the American Thoracic Society released clinical guidelines for the treatment of patients with chronic obstructive pulmonary disease exacerbations.
Despite current guidelines recommending amoxicillin in most children with community-acquired pneumonia (CAP), macrolides and broad-spectrum antibiotics continue to be prescribed for outpatient CAP.
Patients with either central or peripheral pulmonary embolism had positive outcomes with surgical pulmonary embolectomy for peripheral distribution of thrombus.
Patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) had decreased exacerbations after 3 months of commencing budesonide/formoterol treatment.
Switching from intravenous to oral antibiotics in patients with healthcare-associated pneumonia was found to be safe.
Long-term supplemental oxygen does not provide any benefit for patients with stable chronic obstructive pulmonary disease regarding time of death or first hospitalization.